JP2024545602A5 - - Google Patents
Info
- Publication number
- JP2024545602A5 JP2024545602A5 JP2024529302A JP2024529302A JP2024545602A5 JP 2024545602 A5 JP2024545602 A5 JP 2024545602A5 JP 2024529302 A JP2024529302 A JP 2024529302A JP 2024529302 A JP2024529302 A JP 2024529302A JP 2024545602 A5 JP2024545602 A5 JP 2024545602A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163264360P | 2021-11-19 | 2021-11-19 | |
| US63/264,360 | 2021-11-19 | ||
| US202263268775P | 2022-03-02 | 2022-03-02 | |
| US63/268,775 | 2022-03-02 | ||
| US202263377482P | 2022-09-28 | 2022-09-28 | |
| US63/377,482 | 2022-09-28 | ||
| PCT/US2022/050371 WO2023091644A2 (en) | 2021-11-19 | 2022-11-18 | Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024545602A JP2024545602A (ja) | 2024-12-10 |
| JP2024545602A5 true JP2024545602A5 (https=) | 2025-11-27 |
| JPWO2023091644A5 JPWO2023091644A5 (https=) | 2025-11-27 |
Family
ID=86397758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529302A Pending JP2024545602A (ja) | 2021-11-19 | 2022-11-18 | Ｈｓｄ１７ｂ１３関連二本鎖オリゴヌクレオチド組成物及びそれに関連する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240384273A1 (https=) |
| EP (1) | EP4433596A4 (https=) |
| JP (1) | JP2024545602A (https=) |
| WO (1) | WO2023091644A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3899024A4 (en) | 2018-12-21 | 2023-05-31 | Ionis Pharmaceuticals, Inc. | Modulators of hsd17b13 expression |
| US20240352464A1 (en) * | 2023-03-07 | 2024-10-24 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| CN118773194A (zh) * | 2023-06-16 | 2024-10-15 | 施能康医药科技(苏州)有限公司 | 靶向17-β-羟基类固醇脱氢酶13的核酸及其用途 |
| WO2025184661A1 (en) * | 2024-03-01 | 2025-09-04 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2917473T3 (es) * | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| IL314915B1 (en) * | 2017-01-23 | 2026-02-01 | Regeneron Pharma | Variants of 17-beta-hydroxysteroid dehydrogenase and their uses |
| US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CA3086485A1 (en) * | 2017-12-21 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded rna agents |
| JP7507093B2 (ja) * | 2018-03-21 | 2024-06-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法 |
| MX2021003077A (es) * | 2018-09-19 | 2021-05-27 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y metodos de uso. |
| EP3899024A4 (en) * | 2018-12-21 | 2023-05-31 | Ionis Pharmaceuticals, Inc. | Modulators of hsd17b13 expression |
-
2022
- 2022-11-18 JP JP2024529302A patent/JP2024545602A/ja active Pending
- 2022-11-18 WO PCT/US2022/050371 patent/WO2023091644A2/en not_active Ceased
- 2022-11-18 EP EP22896516.6A patent/EP4433596A4/en active Pending
-
2024
- 2024-05-17 US US18/667,824 patent/US20240384273A1/en active Pending